Literature DB >> 24366185

Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome.

Haiyun Yu1, Xiaoyan Liu1, Jian Huang1, Yinhui Zhang1, Roumu Hu1, Jielin Pu1.   

Abstract

Aminoglycosides promote the readthrough of premature stop codons introduced by nonsense mutations to produce full-length proteins in genetic disease models. The read-through effects of different aminoglycosides and PTC124 on HERG gene have yet to be adequately elucidated. The wild-type (WT) or mutant genes were transiently transfected in HEK293 cells. The read-through effect was examined by adding drugs into culture medium for 24 h. Western blot analysis and patch clamping were performed to evaluate the expression and function of the genes. The mRNA levels were determined using qPCR. The results showed that G418 and PTC124 significantly increased the protein expression of R1014X mutant in a dose-dependent manner and produced a full-length protein. The maximal protein levels after G418, gentamicin or PTC124 treatment were 39.1±2.4, 18.6±0.3 or 10.3±1.0%, respectively, of the WT level. Tobramycin did not exhibit a read-through effect. The mRNA levels, however, did not differ between WT and mutant gene. The tail current densities of R1014X channels at 40 mV were 22.57±2.26 pA/pF for G418, 16.21±1.49 pA/pF for gentamicin and 9.62±0.73 pA/pF for PTC124. The leftward shift of the activation curve was corrected only by G418 and gentamicin. The read-through effects of W927X, R863X and E698X revealed that as the mutation site approached the N-terminal, the rescue efficiency was decreased. The above results suggest that aminoglycosides and PTC124 induced different effects on rescue nonsense mutations of the HERG gene. The mutation site was a significant factor in determining the pharmacological rescue efficiency.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24366185     DOI: 10.3892/ijmm.2013.1601

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  14 in total

1.  Stop-codon and C-terminal nonsense mutations are associated with a lower risk of cardiac events in patients with long QT syndrome type 1.

Authors:  Martin H Ruwald; Xiaorong Xu Parks; Arthur J Moss; Wojciech Zareba; Jayson Baman; Scott McNitt; Jorgen K Kanters; Wataru Shimizu; Arthur A Wilde; Christian Jons; Coeli M Lopes
Journal:  Heart Rhythm       Date:  2015-08-28       Impact factor: 6.343

2.  New trends in aminoglycosides use.

Authors:  Marina Y Fosso; Yijia Li; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2014-08-01       Impact factor: 3.597

Review 3.  Shwachman-Diamond Syndrome: Molecular Mechanisms and Current Perspectives.

Authors:  Valentino Bezzerri; Marco Cipolli
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

Review 4.  Nonsense suppression therapies in human genetic diseases.

Authors:  Patrícia Martins-Dias; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2021-03-22       Impact factor: 9.261

5.  Ataluren treatment of patients with nonsense mutation dystrophinopathy.

Authors:  Katharine Bushby; Richard Finkel; Brenda Wong; Richard Barohn; Craig Campbell; Giacomo P Comi; Anne M Connolly; John W Day; Kevin M Flanigan; Nathalie Goemans; Kristi J Jones; Eugenio Mercuri; Ros Quinlivan; James B Renfroe; Barry Russman; Monique M Ryan; Mar Tulinius; Thomas Voit; Steven A Moore; H Lee Sweeney; Richard T Abresch; Kim L Coleman; Michelle Eagle; Julaine Florence; Eduard Gappmaier; Allan M Glanzman; Erik Henricson; Jay Barth; Gary L Elfring; Allen Reha; Robert J Spiegel; Michael W O'donnell; Stuart W Peltz; Craig M Mcdonald
Journal:  Muscle Nerve       Date:  2014-10       Impact factor: 3.217

6.  Translational read-through of the RP2 Arg120stop mutation in patient iPSC-derived retinal pigment epithelium cells.

Authors:  Nele Schwarz; Amanda-Jayne Carr; Amelia Lane; Fabian Moeller; Li Li Chen; Mònica Aguilà; Britta Nommiste; Manickam N Muthiah; Naheed Kanuga; Uwe Wolfrum; Kerstin Nagel-Wolfrum; Lyndon da Cruz; Peter J Coffey; Michael E Cheetham; Alison J Hardcastle
Journal:  Hum Mol Genet       Date:  2014-10-06       Impact factor: 6.150

Review 7.  Nonsense Suppression Therapy: New Hypothesis for the Treatment of Inherited Bone Marrow Failure Syndromes.

Authors:  Valentino Bezzerri; Martina Api; Marisole Allegri; Benedetta Fabrizzi; Seth J Corey; Marco Cipolli
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 8.  Clinical potential of ataluren in the treatment of Duchenne muscular dystrophy.

Authors:  John Hyun Namgoong; Carmen Bertoni
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-05-13

9.  Functional Studies on Novel RET Mutations and Their Implications for Genetic Counseling for Hirschsprung Disease.

Authors:  Hui Wang; Qi Li; Zhen Zhang; Ping Xiao; Long Li; Qian Jiang
Journal:  Front Genet       Date:  2019-10-08       Impact factor: 4.599

10.  Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes.

Authors:  Florian Bolze; Sabine Mocek; Anika Zimmermann; Martin Klingenspor
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.